公开(公告)号：US20180320181A1

公开(公告)日：2018-11-08

申请号：US16021165

申请日：2018-06-28

Applicant: National University Corporation Tokyo Medical and Dental University ,  Osaka University

Inventor： Takanori Yokota ,  Kazutaka Nishina ,  Satoshi Obika ,  Hidehiro Mizusawa

IPC: C12N15/113 ,  C12N15/11

CPC classification number: C12N15/113 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/15 ,  C12N2310/3181 ,  C12N2310/3231 ,  C12N2310/341 ,  C12N2310/3513 ,  C12N2310/3515 ,  C12N2310/53 ,  C12N2320/52

Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

公开(公告)号：US20180284413A1

公开(公告)日：2018-10-04

申请号：US15937684

申请日：2018-03-27

Applicant: OLYMPUS CORPORATION ,  NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY ,  OSAKA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY

Inventor： Hirokazu KUBO ,  Shigehito MIKI ,  Hirotaka TERAI ,  Taro YAMASHITA ,  Tokuko HARAGUCHI ,  Yasushi HIRAOKA ,  Masataka KINJO

IPC: G02B21/18 ,  G02B21/00 ,  G02B21/28 ,  G01N21/64

CPC classification number: G02B21/18 ,  G01N21/6458 ,  G01N2201/0231 ,  G01N2201/06113 ,  G02B21/0048 ,  G02B21/0076 ,  G02B21/008 ,  G02B21/28

Abstract: Provided is a light detecting device including: a light path branching unit that branches a single detection light path of fluorescence from a specimen, into a plurality of branched light paths; a plurality of light detectors that are provided to the respective branched light paths branched by the light path branching unit and that include an SSPD or Geiger mode APD to detect the fluorescence; and a signal adder that generates a single image signal in accordance with the detection signals outputted from the plurality of light detectors.

公开(公告)号：US20180264015A1

公开(公告)日：2018-09-20

申请号：US15762644

申请日：2016-09-29

Applicant: OSAKA UNIVERSITY

Inventor： Nobuyuki TAKAKURA ,  Hisamichi NAITO ,  Kazuhiro TAKARA

IPC: A61K31/662 ,  A61K45/00 ,  A61K35/17 ,  A61P37/04 ,  A61K38/00 ,  A61P35/00 ,  A61K39/395

CPC classification number: A61K31/662 ,  A61K31/683 ,  A61K31/685 ,  A61K35/17 ,  A61K38/005 ,  A61K39/39558 ,  A61K45/00 ,  A61K45/05 ,  A61P35/00 ,  A61P37/04

Abstract: A lysophospholipid receptor-activating substance is able to normalize abnormal blood vessels in tumors without affecting normal blood vessels and to thus induce or promote infiltration of leukocytes into the whole or partial region of a tumor. Therefore, such a lysophospholipid receptor-activating substance is useful as a leukocyte infiltration promoter and an antitumor immunostimulant. Moreover, such a lysophospholipid receptor-activating substance can enhance cancer immunotherapy when used in combination with cancer immunotherapy, and is therefore useful as an agent for enhancing cancer immunotherapy.

公开(公告)号：US10074818B2

公开(公告)日：2018-09-11

申请号：US14906000

申请日：2014-07-09

Applicant: Toppan Forms Co., Ltd. ,  Osaka University ,  The University of Tokyo

Inventor： Takafumi Matsumoto ,  Junichi Takeya

IPC: H01L51/05 ,  H01L51/00 ,  H01L51/10

CPC classification number: H01L51/055 ,  H01L51/0091 ,  H01L51/0545 ,  H01L51/105

Abstract: The transistor includes a gate electrode, an insulating layer, a semiconductor layer, a source electrode, and a drain electrode on a substrate, in which the gate electrode is formed by using silver β-ketocarboxylate denoted by General Formula (1) described below.

公开(公告)号：US10073348B2

公开(公告)日：2018-09-11

申请号：US15241274

申请日：2016-08-19

Applicant: OSAKA UNIVERSITY ,  TOKYO ELECTRON LIMITED ,  JSR CORPORATION

Inventor： Hisashi Nakagawa ,  Takehiko Naruoka ,  Tomoki Nagai ,  Seiichi Tagawa ,  Akihiro Oshima ,  Seiji Nagahara

IPC: G03F7/004 ,  G03F7/20 ,  H01L21/027 ,  C07C309/07 ,  C07C381/12 ,  C08F220/38 ,  C07D409/14 ,  C07C303/32 ,  C08F220/22 ,  C08F220/28 ,  C08F220/26 ,  C08F220/14 ,  G03F7/039 ,  G03F7/32 ,  G03F7/38

CPC classification number: G03F7/203 ,  C07C303/32 ,  C07C309/07 ,  C07C381/12 ,  C07D409/14 ,  C08F220/14 ,  C08F220/22 ,  C08F220/26 ,  C08F220/28 ,  C08F220/38 ,  G03F7/0045 ,  G03F7/0046 ,  G03F7/0397 ,  G03F7/2002 ,  G03F7/2022 ,  G03F7/322 ,  G03F7/38 ,  H01L21/0274

Abstract: A resist-pattern-forming method comprises: patternwise exposing a predetermined region of a resist material film to a first radioactive ray that is ionizing radiation or nonionizing radiation; floodwise exposing the resist material film to a second radioactive ray that is nonionizing radiation; baking the resist material film; and developing the resist material film to form a resist pattern. The resist material film is made from a photosensitive resin composition comprising a chemically amplified resist material. The chemically amplified resist material comprises a base component that is capable of being made soluble or insoluble in a developer solution by an action of an acid and a generative component that is capable of generating a radiation-sensitive sensitizer and an acid upon an exposure. A van der Waals volume of the acid generated from the generative component is no less than 3.0×10−28 m3.

公开(公告)号：US20180252735A1

公开(公告)日：2018-09-06

申请号：US15754817

申请日：2016-08-22

Applicant: OSAKA UNIVERSITY ,  FUJIREBIO INC.

Inventor： Shizuya YAMASHITA ,  Daisaku MASUDA ,  Mitsuo ISOMURA

IPC: G01N33/92 ,  G01N33/577

CPC classification number: G01N33/92 ,  G01N33/577 ,  G01N2800/044

Abstract: Disclosed is a method of distinguishing type III hyperlipidemia in the WHO-classified hyperlipidemia types (hereinafter referred to as type III) from other types of hyperlipidemia, which is a simpler method and has a higher diagnostic efficiency than conventional methods. The method of assisting the determination of type III hyperlipidemia includes the steps of: measuring the apoB-48 value, TG value and LDL-C value in a blood sample isolated from a living body; and calculating a ratio of the apoB-48 value divided by the TG value and a ratio of the apoB-48 value divided by the LDL-C value. In cases where both the ratio of the apoB-48 value divided by the TG value and the ratio of the apoB-48 value divided by the LDL-C value are higher than the respective cut-off values, it indicates that the living body is likely to have type III hyperlipidemia.

公开(公告)号：US20180251488A1

公开(公告)日：2018-09-06

申请号：US15760513

申请日：2016-09-20

Applicant: MITSUBISHI TANABE PHARMA CORPORATION ,  OSAKA UNIVERSITY

Inventor： Satoshi OBIKA ,  Eiji KAWANISHI ,  Hiroaki SAWAMOTO ,  Shuhei YAMAKOSHI ,  Yuuki ARAI ,  Shinji KUMAGAI

IPC: C07H19/06 ,  C07H9/06

CPC classification number: C07H19/06 ,  C07C279/16 ,  C07D498/04 ,  C07D498/08 ,  C07H1/00 ,  C07H9/06 ,  C07H19/16 ,  C07H21/00

Abstract: The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides a method for producing a compound represented by general formula I: (in the formula, R1, R2, R3, R4, R5, R6, m and ring A are as defined in the specification) or a salt thereof wherein a reducing agent is reacted with a compound represented by general formula II: (in the formula, R1, R2, R3, R4, R5, R6, m, and ring A′ are as defined in the specification).

公开(公告)号：US20180243355A1

公开(公告)日：2018-08-30

申请号：US15754687

申请日：2016-08-23

Applicant: OSAKA UNIVERSITY ,  Genomldea Inc.

Inventor： Yasufumi KANEDA ,  Toshihiro NAKAJIMA

IPC: A61K35/76 ,  A61P35/00 ,  C12N7/00 ,  A61K31/713 ,  A61K38/19

CPC classification number: A61K35/76 ,  A61K31/7088 ,  A61K31/713 ,  A61K31/739 ,  A61K38/19 ,  A61K38/195 ,  A61K45/00 ,  A61K48/00 ,  A61P35/00 ,  C12N7/00 ,  C12N2760/18833 ,  C12N2760/18871

Abstract: The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.

公开(公告)号：US20180224464A1

公开(公告)日：2018-08-09

申请号：US15580253

申请日：2015-06-09

Applicant: Osaka University

Inventor： Kazuyuki Yoshizaki ,  Kazuko Uno ,  Mitsuhiro Iwahashi ,  Katsumi Yagi

IPC: G01N33/68 ,  G16H50/70 ,  G16H50/20 ,  G01N33/564

CPC classification number: G01N33/6863 ,  G01N33/564 ,  G01N33/68 ,  G01N33/6893 ,  G01N2800/102 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/60 ,  G16H50/20 ,  G16H50/70

Abstract: The present invention provides a method of predicting and determining a therapeutic effect (especially whether complete remission is reached) or the level of improvement prior to administration of a biological formulation such as an anti-IL-6 agent or an anti-TNF-α agent, which is simple and cost-effective, and accurate. Sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1β, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF, MCP-1, TNF-α, IFN-γ, FGFbasic, PDGF-bb, sIL-6R, MIP-1α and the like can be utilized as a specific marker used in the method. Since a therapeutic effect (level of improvement in a symptom or possibility of remission) on a rheumatoid arthritis patient can be determined prior to the administration of a biological formulation using such a specific marker, rheumatoid arthritis therapy is possible at a precision that could not be achieved conventionally.

公开(公告)号：US20180214410A1

公开(公告)日：2018-08-02

申请号：US15747800

申请日：2016-09-02

Applicant: Osaka University ,  Meiji Co., Ltd.

Inventor： Keisuke Hagihara ,  Kinya Ashida ,  Hidekazu Tonouchi ,  Kentaro Nakamura

IPC: A61K31/225 ,  A61P35/00 ,  A23L33/00 ,  A23L33/115

Abstract: The invention provides new compositions or combinations thereof for the treatment of cancer. More specifically, the invention provides compositions or combinations thereof for cancer treatment including a high-fat diet. Specifically, the high-fat diet is characterized by having approximately 120 g/day or more, or approximately 70% or more of the total daily energy, from fat, based on a real body weight of 50 kg. The diet is preferably a carbohydrate-restricted high-fat diet, and more preferably provided by a ketone formula and/or MCT oil. The dietary therapy by a high-fat diet of the present invention is provided along with surgical treatment, chemotherapy or radiation therapy, or combinations thereof.